Top

Published in:

01-04-2008 | Original Article

Negative predictive value of d-dimer for diagnosis of venous thromboembolism

Authors: Hideki Nomura, Hideo Wada, Toshiro Mizuno, Naoyuki Katayama, Yasunori Abe, Maki Noda, Kaname Nakatani, Takeshi Matsumoto, Satoshi Ota, Norikazu Yamada, Akihiro Sudo, Atsumasa Uchida, Tsutomu Nobori

Published in: International Journal of Hematology | Issue 3/2008

Abstract

The d-dimer levels are considered to be useful for the diagnosis of thrombosis, and they can be clinically used as a negative predictive value (NPV). However, evidence for the efficacy of diagnosing thrombosis based on the d-dimer levels is still not well established. The present study was designed to evaluate the cut-off values of d-dimer levels as a negative predictor for thrombosis. The plasma concentrations of d-dimer were measured in inpatients suspected of having thrombosis, and then the findings were evaluated to assess the correlation with the diagnosis of thrombosis. In healthy volunteers, the median value of VIDAS-d-dimer was 0.12 μg/ml, and the 95% confidence interval was from 0.05 to 0.38 μg/ml. However, the plasma d-dimer levels were significantly higher in patients with thrombosis than in those without thrombosis; there was no significant difference in d-dimer levels among various thromboses such as pulmonary embolism (PE), deep vein thrombosis (DVT), and disseminated intravascular coagulation (DIC). The NPV for venous thromboembolism was 100% in patients with 0.5 μg/ml VIDAS-d-dimer and 1.2 μg/ml LPIA-d-dimer levels. Elevated d-dimer levels might indicate a high risk of thrombosis, especially DVT/PE, and they are thus considered to be useful as a negative predictor for thrombosis.

Linkins LA, Bates SM, Ginsberg JS, Kearon C. Use of different d-dimer levels to exclude venous thromboembolism depending on clinical pretest probability. J Thromb Haemost. 2004;2:1256–60.PubMedCrossRef

Le Gal G, Bounameaux H. Diagnosing pulmonary embolism: running after the decreasing prevalence of cases among suspected patients. J Thromb Haemost. 2004;2:1244–6.PubMedCrossRef

Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost. 2004;2:1247–55.PubMedCrossRef

Wada H, Kobayashi T, Abe Y, Hatada T, Yamada N, Sudo A, Uchida A, Nobori T. Elevated levels of soluble fibrin or d-dimer indicate high risk of thrombosis. J Thromb Haemost. 2006;6:1253–8.CrossRef

Wada H, Sakuragawa N, Shiku H. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients. Semin Thromb Hemost. 1998;24:293–7.PubMedCrossRef

Lehman CM, Wilson LW, Rodgers GM. Analytic validation and clinical evaluation of the STA LIATEST immunoturbidimetric d-dimer assay for the diagnosis of disseminated intravascular coagulation. Am J Clin Pathol. 2004;122:178–84.PubMedCrossRef

Matsumoto T, Wada H, Nobori T, Nakatani K, Onishi K, Nishikawa M, Shiku H, Kazahaya Y, Sawai T, Koike K, Matsuda M. Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2005;11:391–400.PubMedCrossRef

Tanigawa M, Wada H, Minamikawa K, Wakita Y, Nagaya S, Mori T, Tamaki S, Nishikawa H, Kakuta Y, Nakano T, Hayashi T, Suzuki K, Shiku H. Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. Am J Hematol. 1995;49:1–5.PubMedCrossRef

Saito Y, Wada H, Yamamuro M, Inouue A, Shimura M, Hiyoyama K, Gabazza EC, Isaka N, Shiku H, Takeya H, Suzuki K, Kumeda K, Kato H, Nakano T. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. Am J Hematol. 1999;61:238–42.PubMedCrossRef

10.

Wada H, Kaneko T, Ohiwa M, Tanigawa M, Hayashi T, Tamaki S, Minami N, Deguchi K, Suzuki K, Nakano T, Shirakawa S. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol. 1993;44:101–5.PubMedCrossRef

11.

Nieuwenhuizen W. A reference material for harmonization of d-dimer assays. Thromb Haemost. 1997;77:1031–3.PubMed

12.

Dempfle CE, Zips S, Ergül H, Heene DL, the FACT study group. The fibrin assay comparison trial (FACT). Thromb Haemost. 2001;85:671–8.

13.

Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O’Fallon WM, Melton LJ III. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452–63.PubMed

14.

Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83:657–60.

15.

Courtney DM, Kline JA. Identification of prearrest clinical factors associated with outpatient fatal pulmonary embolism. Acad Emerg Med. 2001;8:1136–42.PubMedCrossRef

16.

Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ. Evaluation of d-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349:1227–35.PubMedCrossRef

17.

Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. N Engl J Med. 2003;349:1247–55.PubMedCrossRef

18.

Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost. 1999;82:695–705.PubMed

19.

Wada H. Disseminated intravascular coagulation. Clin Chim Acta. 2004;344:13–21.PubMedCrossRef

20.

Okabayashi K, Wada H, Ohta S, Shiku H, Nobori T, Maruyama K. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol. 2004;76:225–9.PubMedCrossRef

21.

Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Mori Y, Shiku H. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost. 1995;74:848–52.PubMed

22.

Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.PubMed

23.

Matsuda M, Terukina S, Yamazumi K, Maekawa H, Soe G. A monoclonal antibody that recognizes the NH2-terminal conformation of fragment D. In: Matsuda M, Iwanaga S, Takada A, Henschen A, editors. Fibrinogen 4, current basic and clinical aspects. Amsterdam; 1990. p. 43–8.

24.

Goldstein BJ, Mushlin AI. Use of a single thyroxine test to evaluate ambulatory medical patients for suspected hypothyroidism. J Gen Intern Med. 1987;2:20–4.PubMedCrossRef

25.

Pittet JL, de Moerloose P, Reber G, Durand C, Villard C, Piga N, Rolland D, Comby S, Dupuy G. VIDAS d-dimer: fast quantitative ELISA for measuring d-dimer in plasma. Clin Chem. 1996;42:410–5.PubMed

26.

Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost. 1999;82:673–83.PubMed

27.

Minamikawa K, Wada H, Wakita Y, Ohiwa M, Tanigawa M, Deguchi K, Hiraoka N, Huzioka H, Nishioka J, Hayashi T, Shirakawa S, Nakano T, Suzuki K. Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism. Thromb Haemost. 1994;71:192–4.PubMed

28.

Yamada N, Wada H, Nakase T, Minamikawa K, Nagaya S, Nakamura M, Hiraoka N, Fuzioka H, Suzuki K, Nakano T, Shiku H. Hemostatic abnormalities in patients with pulmonary embolism compared with that in deep vein thrombosis. Blood Coagul Fibrinolysis. 1995;6:627–33.PubMedCrossRef

29.

Wada H, Mori Y, Shimura M, Hiyoyama K, Ioka M, Nakasaki T, Nishikawa M, Nakano M, Kumeda K, Kaneko T, Nakamura S, Shiku H. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol. 1998;58:189–94.PubMedCrossRef

30.

Wada H, Mori Y, Kaneko T, Wakita Y, Nakase T, Minamikawa K, Ohiwa M, Tamaki S, Tanigawa M, Kageyama S, Deguchi K, Nakano T, Shirakawa S, Suzuki K. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol. 1993;44:112–6.PubMedCrossRef

31.

Ota S, Wada H, Nobori T, Kobayashi T, Nishio M, Nishioka Y, Noda M, Sakaguchi A, Abe Y, Nishioka J, Ishikura K, Yamada N, Nakano T. Diagnosis of deep vein thrombosis by plasma-soluble fibrin or d-dimer. Am J Hematol. 2005;79:274–80.PubMedCrossRef

32.

Kline JA, Wells PS. Methodology for a rapid protocol to rule out pulmonary embolism in the emergency department. Ann Emerg Med. 2003;42:266–75.PubMedCrossRef

Title: Negative predictive value of d-dimer for diagnosis of venous thromboembolism
Authors: Hideki Nomura
Hideo Wada
Toshiro Mizuno
Naoyuki Katayama
Yasunori Abe
Maki Noda
Kaname Nakatani
Takeshi Matsumoto
Satoshi Ota
Norikazu Yamada
Akihiro Sudo
Atsumasa Uchida
Tsutomu Nobori
Publication date: 01-04-2008
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 3/2008
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-008-0047-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution

A case of adult Langerhans cell histiocytosis showing successfully regenerated osseous tissue of the skull after chemotherapy

Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells

The evaluation of hTERT mRNA expression in acute leukemia children and 2 years follow-up of 40 cases

A case of factor X (FX) deficiency due to novel mutation V196M, FX Hofu

Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer